Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

P. W. Hellings, P. W. Hellings, P. W. Hellings, W. J. Fokkens, C. Bachert, C. Bachert, C. A. Akdis, T. Bieber, I. Agache, M. Bernal-Sprekelsen, G. W. Canonica, P. Gevaert, G. Joos, V. Lund, A. Muraro, M. Onerci, T. Zuberbier, B. Pugin, S. F. Seys, S. F. SeysJ. Bousquet, W. Aberer, I. Agache, C. A. Akdis, M. Akdis, I. Alobid, J. Ankri, I. Annesi-Maesano, I. J. Ansotegui, J. M. Anto, S. Arnavielhe, H. Arshad, A. Asarnoj, F. Avolio, C. Bachert, C. Bachert, I. Baiardini, M. Barbagallo, C. Barbara, F. Baroody, E. D. Bateman, A. Bedbrook, B. Beghé, E. H. Bel, K. S. Bennoor, M. Benson, K. C. Bergmann, M. Bewick, A. Z. Bialoszewski, T. Bieber, C. Bindslev-Jensen, L. Bjermer, H. Blain, F. Blasi, A. L. Boner, M. Bonini, S. Bonini, S. Bosnic-Anticevich, I. Bosse, J. Bouchard, L. P. Boulet, R. Bourret, J. Bousquet, P. J. Bousquet, F. Braido, A. H. Briggs, C. E. Brightling, J. Brozek, C. Bucca, R. Buhl, C. Bunu, E. Burte, A. Bush, F. Caballero-Fonseca, D. P. Caimmi, M. A. Calderon, P. A. Camargos, T. Camuzat, G. W. Canonica, V. Cardona, K. H. Carlsen, W. Carr, P. Carreiro-Martins, A. M. Carriazo, T. Casale, A. M. Cepeda Sarabia, A. Cervin, M. Cesari, L. Chatzi, N. H. Chavannes, R. Chiron, T. Chivato, E. Chkhartishvili, A. G. Chuchalin, K. F. Chung, G. Ciprandi, N. Cohen, S. Conzález Diaz, L. Cox, G. Crooks

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.
Original languageEnglish
Pages (from-to)1297-1305
Number of pages9
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume72
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Precision Medicine
Patient Participation
Therapeutics
Allergic Rhinitis
Tertiary Healthcare
Patient Satisfaction
Disease Progression
Patient Care
Hypersensitivity
Chronic Disease

Keywords

  • allergic rhinitis
  • integrated care pathway
  • precision medicine
  • rhinosinusitis

Cite this

Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. / Hellings, P. W.; Hellings, P. W.; Hellings, P. W.; Fokkens, W. J.; Bachert, C.; Bachert, C.; Akdis, C. A.; Bieber, T.; Agache, I.; Bernal-Sprekelsen, M.; Canonica, G. W.; Gevaert, P.; Joos, G.; Lund, V.; Muraro, A.; Onerci, M.; Zuberbier, T.; Pugin, B.; Seys, S. F.; Seys, S. F.; Bousquet, J.; Aberer, W.; Agache, I.; Akdis, C. A.; Akdis, M.; Alobid, I.; Ankri, J.; Annesi-Maesano, I.; Ansotegui, I. J.; Anto, J. M.; Arnavielhe, S.; Arshad, H.; Asarnoj, A.; Avolio, F.; Bachert, C.; Bachert, C.; Baiardini, I.; Barbagallo, M.; Barbara, C.; Baroody, F.; Bateman, E. D.; Bedbrook, A.; Beghé, B.; Bel, E. H.; Bennoor, K. S.; Benson, M.; Bergmann, K. C.; Bewick, M.; Bialoszewski, A. Z.; Bieber, T.; Bindslev-Jensen, C.; Bjermer, L.; Blain, H.; Blasi, F.; Boner, A. L.; Bonini, M.; Bonini, S.; Bosnic-Anticevich, S.; Bosse, I.; Bouchard, J.; Boulet, L. P.; Bourret, R.; Bousquet, J.; Bousquet, P. J.; Braido, F.; Briggs, A. H.; Brightling, C. E.; Brozek, J.; Bucca, C.; Buhl, R.; Bunu, C.; Burte, E.; Bush, A.; Caballero-Fonseca, F.; Caimmi, D. P.; Calderon, M. A.; Camargos, P. A.; Camuzat, T.; Canonica, G. W.; Cardona, V.; Carlsen, K. H.; Carr, W.; Carreiro-Martins, P.; Carriazo, A. M.; Casale, T.; Cepeda Sarabia, A. M.; Cervin, A.; Cesari, M.; Chatzi, L.; Chavannes, N. H.; Chiron, R.; Chivato, T.; Chkhartishvili, E.; Chuchalin, A. G.; Chung, K. F.; Ciprandi, G.; Cohen, N.; Conzález Diaz, S.; Cox, L.; Crooks, G.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, No. 9, 01.09.2017, p. 1297-1305.

Research output: Contribution to journalArticle

Hellings, PW, Hellings, PW, Hellings, PW, Fokkens, WJ, Bachert, C, Bachert, C, Akdis, CA, Bieber, T, Agache, I, Bernal-Sprekelsen, M, Canonica, GW, Gevaert, P, Joos, G, Lund, V, Muraro, A, Onerci, M, Zuberbier, T, Pugin, B, Seys, SF, Seys, SF, Bousquet, J, Aberer, W, Agache, I, Akdis, CA, Akdis, M, Alobid, I, Ankri, J, Annesi-Maesano, I, Ansotegui, IJ, Anto, JM, Arnavielhe, S, Arshad, H, Asarnoj, A, Avolio, F, Bachert, C, Bachert, C, Baiardini, I, Barbagallo, M, Barbara, C, Baroody, F, Bateman, ED, Bedbrook, A, Beghé, B, Bel, EH, Bennoor, KS, Benson, M, Bergmann, KC, Bewick, M, Bialoszewski, AZ, Bieber, T, Bindslev-Jensen, C, Bjermer, L, Blain, H, Blasi, F, Boner, AL, Bonini, M, Bonini, S, Bosnic-Anticevich, S, Bosse, I, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, J, Bousquet, PJ, Braido, F, Briggs, AH, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Bunu, C, Burte, E, Bush, A, Caballero-Fonseca, F, Caimmi, DP, Calderon, MA, Camargos, PA, Camuzat, T, Canonica, GW, Cardona, V, Carlsen, KH, Carr, W, Carreiro-Martins, P, Carriazo, AM, Casale, T, Cepeda Sarabia, AM, Cervin, A, Cesari, M, Chatzi, L, Chavannes, NH, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciprandi, G, Cohen, N, Conzález Diaz, S, Cox, L & Crooks, G 2017, 'Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement', Allergy: European Journal of Allergy and Clinical Immunology, vol. 72, no. 9, pp. 1297-1305. https://doi.org/10.1111/all.13162
Hellings, P. W. ; Hellings, P. W. ; Hellings, P. W. ; Fokkens, W. J. ; Bachert, C. ; Bachert, C. ; Akdis, C. A. ; Bieber, T. ; Agache, I. ; Bernal-Sprekelsen, M. ; Canonica, G. W. ; Gevaert, P. ; Joos, G. ; Lund, V. ; Muraro, A. ; Onerci, M. ; Zuberbier, T. ; Pugin, B. ; Seys, S. F. ; Seys, S. F. ; Bousquet, J. ; Aberer, W. ; Agache, I. ; Akdis, C. A. ; Akdis, M. ; Alobid, I. ; Ankri, J. ; Annesi-Maesano, I. ; Ansotegui, I. J. ; Anto, J. M. ; Arnavielhe, S. ; Arshad, H. ; Asarnoj, A. ; Avolio, F. ; Bachert, C. ; Bachert, C. ; Baiardini, I. ; Barbagallo, M. ; Barbara, C. ; Baroody, F. ; Bateman, E. D. ; Bedbrook, A. ; Beghé, B. ; Bel, E. H. ; Bennoor, K. S. ; Benson, M. ; Bergmann, K. C. ; Bewick, M. ; Bialoszewski, A. Z. ; Bieber, T. ; Bindslev-Jensen, C. ; Bjermer, L. ; Blain, H. ; Blasi, F. ; Boner, A. L. ; Bonini, M. ; Bonini, S. ; Bosnic-Anticevich, S. ; Bosse, I. ; Bouchard, J. ; Boulet, L. P. ; Bourret, R. ; Bousquet, J. ; Bousquet, P. J. ; Braido, F. ; Briggs, A. H. ; Brightling, C. E. ; Brozek, J. ; Bucca, C. ; Buhl, R. ; Bunu, C. ; Burte, E. ; Bush, A. ; Caballero-Fonseca, F. ; Caimmi, D. P. ; Calderon, M. A. ; Camargos, P. A. ; Camuzat, T. ; Canonica, G. W. ; Cardona, V. ; Carlsen, K. H. ; Carr, W. ; Carreiro-Martins, P. ; Carriazo, A. M. ; Casale, T. ; Cepeda Sarabia, A. M. ; Cervin, A. ; Cesari, M. ; Chatzi, L. ; Chavannes, N. H. ; Chiron, R. ; Chivato, T. ; Chkhartishvili, E. ; Chuchalin, A. G. ; Chung, K. F. ; Ciprandi, G. ; Cohen, N. ; Conzález Diaz, S. ; Cox, L. ; Crooks, G. / Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. In: Allergy: European Journal of Allergy and Clinical Immunology. 2017 ; Vol. 72, No. 9. pp. 1297-1305.
@article{0d9e569c8c76468f85e6721d4376a672,
title = "Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement",
abstract = "{\circledC} 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.",
keywords = "allergic rhinitis, integrated care pathway, precision medicine, rhinosinusitis",
author = "Hellings, {P. W.} and Hellings, {P. W.} and Hellings, {P. W.} and Fokkens, {W. J.} and C. Bachert and C. Bachert and Akdis, {C. A.} and T. Bieber and I. Agache and M. Bernal-Sprekelsen and Canonica, {G. W.} and P. Gevaert and G. Joos and V. Lund and A. Muraro and M. Onerci and T. Zuberbier and B. Pugin and Seys, {S. F.} and Seys, {S. F.} and J. Bousquet and W. Aberer and I. Agache and Akdis, {C. A.} and M. Akdis and I. Alobid and J. Ankri and I. Annesi-Maesano and Ansotegui, {I. J.} and Anto, {J. M.} and S. Arnavielhe and H. Arshad and A. Asarnoj and F. Avolio and C. Bachert and C. Bachert and I. Baiardini and M. Barbagallo and C. Barbara and F. Baroody and Bateman, {E. D.} and A. Bedbrook and B. Begh{\'e} and Bel, {E. H.} and Bennoor, {K. S.} and M. Benson and Bergmann, {K. C.} and M. Bewick and Bialoszewski, {A. Z.} and T. Bieber and C. Bindslev-Jensen and L. Bjermer and H. Blain and F. Blasi and Boner, {A. L.} and M. Bonini and S. Bonini and S. Bosnic-Anticevich and I. Bosse and J. Bouchard and Boulet, {L. P.} and R. Bourret and J. Bousquet and Bousquet, {P. J.} and F. Braido and Briggs, {A. H.} and Brightling, {C. E.} and J. Brozek and C. Bucca and R. Buhl and C. Bunu and E. Burte and A. Bush and F. Caballero-Fonseca and Caimmi, {D. P.} and Calderon, {M. A.} and Camargos, {P. A.} and T. Camuzat and Canonica, {G. W.} and V. Cardona and Carlsen, {K. H.} and W. Carr and P. Carreiro-Martins and Carriazo, {A. M.} and T. Casale and {Cepeda Sarabia}, {A. M.} and A. Cervin and M. Cesari and L. Chatzi and Chavannes, {N. H.} and R. Chiron and T. Chivato and E. Chkhartishvili and Chuchalin, {A. G.} and Chung, {K. F.} and G. Ciprandi and N. Cohen and {Conz{\'a}lez Diaz}, S. and L. Cox and G. Crooks",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/all.13162",
language = "English",
volume = "72",
pages = "1297--1305",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

AU - Hellings, P. W.

AU - Hellings, P. W.

AU - Hellings, P. W.

AU - Fokkens, W. J.

AU - Bachert, C.

AU - Bachert, C.

AU - Akdis, C. A.

AU - Bieber, T.

AU - Agache, I.

AU - Bernal-Sprekelsen, M.

AU - Canonica, G. W.

AU - Gevaert, P.

AU - Joos, G.

AU - Lund, V.

AU - Muraro, A.

AU - Onerci, M.

AU - Zuberbier, T.

AU - Pugin, B.

AU - Seys, S. F.

AU - Seys, S. F.

AU - Bousquet, J.

AU - Aberer, W.

AU - Agache, I.

AU - Akdis, C. A.

AU - Akdis, M.

AU - Alobid, I.

AU - Ankri, J.

AU - Annesi-Maesano, I.

AU - Ansotegui, I. J.

AU - Anto, J. M.

AU - Arnavielhe, S.

AU - Arshad, H.

AU - Asarnoj, A.

AU - Avolio, F.

AU - Bachert, C.

AU - Bachert, C.

AU - Baiardini, I.

AU - Barbagallo, M.

AU - Barbara, C.

AU - Baroody, F.

AU - Bateman, E. D.

AU - Bedbrook, A.

AU - Beghé, B.

AU - Bel, E. H.

AU - Bennoor, K. S.

AU - Benson, M.

AU - Bergmann, K. C.

AU - Bewick, M.

AU - Bialoszewski, A. Z.

AU - Bieber, T.

AU - Bindslev-Jensen, C.

AU - Bjermer, L.

AU - Blain, H.

AU - Blasi, F.

AU - Boner, A. L.

AU - Bonini, M.

AU - Bonini, S.

AU - Bosnic-Anticevich, S.

AU - Bosse, I.

AU - Bouchard, J.

AU - Boulet, L. P.

AU - Bourret, R.

AU - Bousquet, J.

AU - Bousquet, P. J.

AU - Braido, F.

AU - Briggs, A. H.

AU - Brightling, C. E.

AU - Brozek, J.

AU - Bucca, C.

AU - Buhl, R.

AU - Bunu, C.

AU - Burte, E.

AU - Bush, A.

AU - Caballero-Fonseca, F.

AU - Caimmi, D. P.

AU - Calderon, M. A.

AU - Camargos, P. A.

AU - Camuzat, T.

AU - Canonica, G. W.

AU - Cardona, V.

AU - Carlsen, K. H.

AU - Carr, W.

AU - Carreiro-Martins, P.

AU - Carriazo, A. M.

AU - Casale, T.

AU - Cepeda Sarabia, A. M.

AU - Cervin, A.

AU - Cesari, M.

AU - Chatzi, L.

AU - Chavannes, N. H.

AU - Chiron, R.

AU - Chivato, T.

AU - Chkhartishvili, E.

AU - Chuchalin, A. G.

AU - Chung, K. F.

AU - Ciprandi, G.

AU - Cohen, N.

AU - Conzález Diaz, S.

AU - Cox, L.

AU - Crooks, G.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.

AB - © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.

KW - allergic rhinitis

KW - integrated care pathway

KW - precision medicine

KW - rhinosinusitis

UR - http://www.scopus.com/inward/record.url?scp=85019855955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019855955&partnerID=8YFLogxK

U2 - 10.1111/all.13162

DO - 10.1111/all.13162

M3 - Article

AN - SCOPUS:85019855955

VL - 72

SP - 1297

EP - 1305

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -